Acutus Medical, Inc.

Safety Score

Market Cap $1.79M
Debt $41.21M
Cash $12.60M
EV $30.41M
FCF -$28.98M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$41.91M
EBIT	$35.91M
ROA	112%
FCF	-$28.98M
Equity	-$10.30M
Growth Stability	1
PE	-0.04
PB	-0.17
P/FCF	-0.06
P/S	0.33
Price/Cash	7.03
Debt/Equity	-4
Debt/FCF	-1.42
Net Margins	-62%
Gross Margins	102%
Op. Margins	654%
Sales Growth YoY	1%
Sales Growth QoQ	28%
Sales CAGR	-0%
Equity CAGR	-6%
Earnings Growth YoY	-58%

Earnings Growth QoQ	513%
Sales CAGR 5Y	-0%
Equity CAGR 5Y	-7%
Earnings CAGR 3Y	-37%
Sales CAGR 3Y	-37%
Equity CAGR 3Y	-7%
Market Cap	$1.79M
Revenue	$5.50M
Assets	$32.17M
Total Debt	$41.21M
Cash	$12.60M
Shares Outstanding	29.31M
EV	30.41M
Safety Score	39%
Working Capital	12.49M
Current Ratio	1.85
Gross Profit	$5.62M
Shares Growth 3y	2%
Equity Growth QoQ	114%
Equity Growth YoY	-132%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Europe.

SEC Filings

Direct access to Acutus Medical, Inc. (AFIB) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Acutus Medical, Inc. compare to its competitors?

Not enough data to generate a comparison chart between Acutus Medical, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Acutus Medical, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Acutus Medical, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Acutus Medical, Inc..

Years

Calculation mode

= -$290M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$29M	-$29M	-$29M	-$29M	-$29M	-$29M	-$29M	-$29M	-$29M	-$29M	-$29M	-$290M
DCF		-$26M	-$24M	-$22M	-$20M	-$18M	-$16M	-$15M	-$14M	-$12M	-$11M	-$112M
Value	-$290M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-3K%	-1K%	-682%	-242%	-1K%	-62%
ROA	-	-47%	-66%	-20%	-22%	112%
ROE	-	-81%	-111%	-53%	9K%	-

Bad Net Margins (-62.49%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.46	-0.41	-1.06	-1.93	-1.42
Debt over Equity	-0.2	0.35	0.42	0.49	-43.98	-4
Growth Stability	-	-	-	-	-	1

Good Debt/FCF ratio (-1.42)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-4)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	198%	104%	-5%	-56%	-0%
Earnings YoY growth	-	5%	15%	-66%	106%	-
Equity YoY growth	-	-156%	-16%	-29%	-101%	-7%
FCF YoY growth	-	62%	14%	-68%	-42%	-